Please assess the completion status of the following clinical trial:

Trial Title: Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. All subjects must be female~2. Postmenopausal status, defined as any one of the following criteria:~   1. documented history of bilateral oophorectomy;~  2. age 60 years or more;~  3. ages 45 to 59 and satisfying one or more of the following criteria:~      * amenorrhea for at least 12 months and intact uterus;~     * amenorrhea for less than 12 months and a follicle stimulating hormone (FSH) concentration within premenopausal range including:~        * patients who have had a hysterectomy;~       * patients who have received hormone replacement.~3. Patients must have histologically confirmed invasive breast cancer with a primary tumor of 3 cm or more in greatest dimension as measured by clinical examination.~4. Estrogen receptor and/or progesterone receptor positive disease~5. Patients must not have received any prior treatment for current or newly diagnosed breast cancer.~6. Patients must have not received previous treatment with any of the study medications or similar drugs.~7. No use of selective estrogen receptor modulators (SERM) such as raloxifene or similar agents in the past 2 years.~8. World Health Organization (WHO) performance status of 0, 1, or 2~9. Adequate organ function defined as follows:~   1. adequate renal function, defined by a serum creatinine within 3 times the upper limits of normal;~  2. adequate liver function, defined by total bilirubin, AST, ALT, and alkaline phosphatase within 3 times the upper limits of normal;~  3. adequate bone marrow function, defined as a white blood cell (WBC) \> 3.0 ml, platelet (PLT) \> 75,000/ul, hemoglobin (Hb) \> 9 gm/l~10. Willing to undergo breast core biopsies as required by the study protocol~11. Ability to understand and sign a written informed consent for participation in the trial~12. Life expectancy of at least 1 year.~Exclusion Criteria:~1. Known severe hypersensitivity to Iressa or any of the excipients of this product~2. Premenopausal status~3. Patients with synchronous bilateral breast cancer~4. Patients with diffuse tumors that cannot be clearly measurable, such as inflammatory breast cancer~5. Other coexisting malignancies with the exception of basal cell carcinoma or cervical cancer in situ~6. Patients with brain metastasis~7. WHO performance status of 3 or 4~8. As judged by the investigator, uncontrolled intercurrent illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.~9. Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the clinical trial.~10. Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or St. John's wort~11. Concurrent treatment with estrogens or progestins. Patients must stop these drugs at least two weeks prior to study entry.~12. Treatment with a non-approved or investigational drug within 30 days before Day 1 of study treatment~13. Platelet count less than 75,000~14. In the opinion of the investigator, bleeding diathesis or anticoagulation therapy that would preclude intramuscular injections.~15. History of hypersensitivity to castor oil~16. Any evidence of clinically active interstitial lung disease (patients with chronic stable radiographic changes who are asymptomatic need not be excluded).~17. Patients with recurrent breast cancer. Patients with contralateral second primary breast cancers are eligible.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Iressa Day 1 with Arimidex and Faslodex (Type: EXPERIMENTAL): Subjects randomized to Iressa on Day 1 in combination with Arimidex and Faslodex.
- Iressa Day 21 with Arimidex and Faslodex (Type: ACTIVE_COMPARATOR): Subjects randomized to Iressa Day 21 in combination with Arimidex and Faslodex

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues